Latest Financial Results News

Clinuvel Pharmaceuticals reports steady financial growth with an 8% rise in revenue and 2% profit increase, while expanding its US commercial footprint and completing recruitment for a pivotal vitiligo trial.

Comms Group delivered FY25 results at the upper end of guidance, boosted by record new sales and the acquisition of TasmaNet. The company sets sights on accelerated growth and integration benefits in FY26.

Cromwell Property Group reported a 15% drop in revenue and a 21% fall in operating profit for FY2025, yet significantly reduced its losses and net debt, signaling cautious progress amid challenging market conditions.

Shine Justice Ltd reported a revenue increase to $204.4 million in FY25 despite a dip in adjusted net profit after tax, driven by strategic restructuring and a sharpened focus on personal injury and international mass torts. The company is investing in technology and expanding its US footprint to fuel growth in FY26.

Ramsay Health Care has announced a fully franked ordinary dividend of AUD 0.40 per share for the six months ending June 2025, signaling steady returns for shareholders.

SomnoMed delivered a strong FY25 performance with revenue climbing 22% to $111.5 million and EBITDA turning positive at $9.2 million, boosted by operational improvements and FDA clearance of its Rest Assure device. The company projects further growth in FY26 with expanded manufacturing and ongoing innovation.

Raiz Invest reported robust FY25 results with 15% revenue growth and a near break-even net loss, underpinned by strong customer and funds growth. The fintech’s strategic innovations and partnerships set a positive tone for FY26.

Raiz Invest Limited reported robust FY25 results with revenue up 14.5% and underlying EBITDA surging 147.5%, while completing its exit from Southeast Asia and launching the new Raiz Lite product.

Westgold Resources Limited has announced a 3 cent per share final dividend for the financial year ending June 2025, payable in October. The dividend is unfranked, reflecting the company’s current tax position.

Zoono Group Limited reported a 19.1% revenue increase to NZ$1.25 million for FY2025, alongside a significantly reduced net loss. The company is pivoting towards B2B markets, focusing on antimicrobial and shelf-life extension technologies, supported by a recent AUD 1.78 million capital raise.

Tetratherix Limited reports its first financial results as a listed company, revealing a $9.4 million statutory loss driven by R&D and listing costs, alongside a robust $29.3 million cash position post-IPO. The company highlights key operational milestones and outlines strategic plans to accelerate commercialisation across its innovative biomaterial platform.

Perpetual Limited reported a steady underlying profit for FY25, achieving significant cost savings while navigating asset management outflows and advancing the sale of its Wealth Management division.